DD141163A5 - Verfahren zur herstellung einer heterovakzine - Google Patents

Verfahren zur herstellung einer heterovakzine Download PDF

Info

Publication number: DD141163A5
Authority: DD; German Democratic Republic
Prior art keywords: cbs; strains; vaccine; microorganisms; inactivated
Prior art date: 1977-12-23

Application number

DD78210129A

Other languages

German (de)

English (en)

Inventor

Ljubinko Stojkovic

Original Assignee

Solco Basel Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-12-23

Filing date

1978-12-22

Publication date

1980-04-16

1978-12-22 Application filed by Solco Basel Ag filed Critical Solco Basel Ag

1980-04-16 Publication of DD141163A5 publication Critical patent/DD141163A5/de

Links

238000004519 manufacturing process Methods 0.000 title description 7
229960005486 vaccine Drugs 0.000 claims abstract description 41
244000005700 microbiome Species 0.000 claims abstract description 23
238000011282 treatment Methods 0.000 claims abstract description 19
208000011580 syndromic disease Diseases 0.000 claims abstract description 12
241000224526 Trichomonas Species 0.000 claims abstract description 11
238000009395 breeding Methods 0.000 claims abstract description 4
230000001488 breeding effect Effects 0.000 claims abstract description 4
230000001225 therapeutic effect Effects 0.000 claims abstract description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 24
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 16
238000000034 method Methods 0.000 claims description 16
230000002779 inactivation Effects 0.000 claims description 9
239000012620 biological material Substances 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 4
239000012531 culture fluid Substances 0.000 claims description 3
239000003755 preservative agent Substances 0.000 claims description 2
230000002335 preservative effect Effects 0.000 claims description 2
230000036039 immunity Effects 0.000 abstract 1
239000000243 solution Substances 0.000 description 18
238000002255 vaccination Methods 0.000 description 12
238000012360 testing method Methods 0.000 description 11
208000015181 infectious disease Diseases 0.000 description 10
239000002609 medium Substances 0.000 description 10
210000002966 serum Anatomy 0.000 description 8
239000000725 suspension Substances 0.000 description 7
239000000910 agglutinin Substances 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
210000001215 vagina Anatomy 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
241000224527 Trichomonas vaginalis Species 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
230000036512 infertility Effects 0.000 description 5
239000000463 material Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 4
235000015097 nutrients Nutrition 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
101710186708 Agglutinin Proteins 0.000 description 3
101710146024 Horcolin Proteins 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
101710189395 Lectin Proteins 0.000 description 3
101710179758 Mannose-specific lectin Proteins 0.000 description 3
101710150763 Mannose-specific lectin 1 Proteins 0.000 description 3
101710150745 Mannose-specific lectin 2 Proteins 0.000 description 3
206010046914 Vaginal infection Diseases 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
210000003679 cervix uteri Anatomy 0.000 description 3
201000010099 disease Diseases 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
229960000282 metronidazole Drugs 0.000 description 3
239000002504 physiological saline solution Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
239000001888 Peptone Substances 0.000 description 2
108010080698 Peptones Proteins 0.000 description 2
208000035415 Reinfection Diseases 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
208000005448 Trichomonas Infections Diseases 0.000 description 2
206010044620 Trichomoniasis Diseases 0.000 description 2
239000003708 ampul Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
206010008323 cervicitis Diseases 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
201000003988 chronic cervicitis Diseases 0.000 description 2
238000002573 colposcopy Methods 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
208000019993 erythroplakia Diseases 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
230000007774 longterm Effects 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000008520 organization Effects 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
235000019319 peptone Nutrition 0.000 description 2
239000011833 salt mixture Substances 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
XWBADQOPXPRKBX-FMIVXFBMSA-N 1-n,1-n-diethyl-4-n-[6-methoxy-2-[(e)-2-(4-nitrophenyl)ethenyl]quinolin-4-yl]pentane-1,4-diamine Chemical compound N=1C2=CC=C(OC)C=C2C(NC(C)CCCN(CC)CC)=CC=1\C=C\C1=CC=C([N+]([O-])=O)C=C1 XWBADQOPXPRKBX-FMIVXFBMSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
101000588924 Anthopleura elegantissima Delta-actitoxin-Ael1a Proteins 0.000 description 1
241000304886 Bacilli Species 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
208000004483 Dyspareunia Diseases 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
206010051998 Febrile infection Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
206010018612 Gonorrhoea Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
240000001046 Lactobacillus acidophilus Species 0.000 description 1
235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001375804 Mastigophora Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
-1 Polyoxyethylene Polymers 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
206010064899 Vulvovaginal mycotic infection Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
238000011374 additional therapy Methods 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
210000003152 adnexa uteri Anatomy 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
229940058965 antiprotozoal agent against amoebiasis and other protozoal diseases nitroimidazole derivative Drugs 0.000 description 1
239000003716 antitrichomonal agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000006161 blood agar Substances 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
210000003756 cervix mucus Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
206010013990 dysuria Diseases 0.000 description 1
201000003511 ectopic pregnancy Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000008508 epithelial proliferation Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
208000001786 gonorrhea Diseases 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000000951 immunodiffusion Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
229940039695 lactobacillus acidophilus Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
150000004957 nitroimidazoles Chemical class 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
238000009595 pap smear Methods 0.000 description 1
244000045947 parasite Species 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000001373 regressive effect Effects 0.000 description 1
210000005000 reproductive tract Anatomy 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002689 soil Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229950004959 sorbitan oleate Drugs 0.000 description 1
238000003892 spreading Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
238000013190 sterility testing Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
239000001973 thioglycolate broth Substances 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
239000001393 triammonium citrate Substances 0.000 description 1
235000011046 triammonium citrate Nutrition 0.000 description 1
208000006685 tubal pregnancy Diseases 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DD78210129A 1977-12-23 1978-12-22 Verfahren zur herstellung einer heterovakzine DD141163A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH1601277A CH639280A5 (de)	1977-12-23	1977-12-23	Verfahren zur herstellung einer vakzine gegen das trichomonas-syndrom.

Publications (1)

Publication Number	Publication Date
DD141163A5 true DD141163A5 (de)	1980-04-16

Family

ID=4413782

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD78210129A DD141163A5 (de)	1977-12-23	1978-12-22	Verfahren zur herstellung einer heterovakzine

Country Status (30)

Country	Link
US (1)	US4238478A (da)
JP (1)	JPS54140716A (da)
KR (1)	KR820000045B1 (da)
AR (1)	AR220548A1 (da)
AT (1)	AT368390B (da)
AU (1)	AU521538B2 (da)
BE (1)	BE872884A (da)
CA (1)	CA1119095A (da)
CH (1)	CH639280A5 (da)
DD (1)	DD141163A5 (da)
DE (1)	DE2854723C3 (da)
DK (1)	DK152174C (da)
EG (1)	EG14095A (da)
ES (1)	ES476703A1 (da)
FI (1)	FI65166C (da)
FR (1)	FR2412314A1 (da)
GB (1)	GB2010677B (da)
GR (1)	GR65648B (da)
IL (1)	IL56177A (da)
IN (1)	IN150348B (da)
IT (1)	IT1109099B (da)
MX (1)	MX5876E (da)
NL (1)	NL179543C (da)
NO (1)	NO149316C (da)
PH (1)	PH16435A (da)
PL (1)	PL117618B1 (da)
SE (1)	SE431400B (da)
SU (1)	SU997599A3 (da)
YU (1)	YU42170B (da)
ZA (1)	ZA786978B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE59079B1 (en) *	1986-11-05	1994-01-12	Oldcastle Veterinary Research	A method of preparing an autogenous vaccine
US5512288A (en) *	1992-12-04	1996-04-30	University Technologies International, Inc.	Giardia vaccine
US5549899A (en)	1992-12-04	1996-08-27	University Technologies International, Inc.	Giardia vaccine
CA2156859A1 (en) *	1993-02-24	1994-09-01	Sherwood L. Gorbach	Method of enhancing immune response to oral vaccines
HU227086B1 (en) *	1999-11-25	2010-06-28	Vakcina Kft	Lactobacillus vaccine for treating prostata inflammatory and benign prostata hyperplasia
DE102004046391A1 (de) *	2004-09-24	2006-04-06	Bioveta Ag	Neuer Impfstoff für veterinäre und humanmedizinische Prophylaxe und Therapie
CN117547556A (zh) *	2023-02-24	2024-02-13	鼎正新兴生物技术（天津）有限公司	一种禽毛滴虫病治疗药物及制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB190925675A (en) *	1908-11-07	1910-02-17	August Wassermann	Substances Serving for the Local Immunisation of Diseased Tissues, and Methods of Preparing same.
FR2946M (fr) *	1963-08-27	1964-12-24	Salvoxyl Lab	Médicament d'origine biologique, en particulier pour la reconstitution de la flore intestinale.
FR6836M (da) *	1967-11-29	1969-03-31
DK127268A (da) *	1970-01-12	1900-01-01
US3957974A (en) *	1974-11-05	1976-05-18	Seikenkai	Method for deodorization of excrements
JPS5218879A (en) *	1975-06-24	1977-02-12	Seikenkai	Method for culturing a stool deodorant germ belonging to lactobacillus genus
JPS52102419A (en) *	1976-02-23	1977-08-27	Seikenkai	Lactic acid producing bacillus preparation
JPS52154590A (en) *	1976-05-21	1977-12-22	Seikenkai	Cultivating and preserving method of deodorising lactobucillus and liling cell preparation

1977
- 1977-12-23 CH CH1601277A patent/CH639280A5/de not_active IP Right Cessation
1978
- 1978-12-11 IL IL56177A patent/IL56177A/xx unknown
- 1978-12-12 YU YU3030/78A patent/YU42170B/xx unknown
- 1978-12-12 GR GR57850A patent/GR65648B/el unknown
- 1978-12-12 AT AT0883578A patent/AT368390B/de not_active IP Right Cessation
- 1978-12-12 IN IN895/DEL/78A patent/IN150348B/en unknown
- 1978-12-13 ZA ZA00786978A patent/ZA786978B/xx unknown
- 1978-12-14 DK DK562178A patent/DK152174C/da not_active IP Right Cessation
- 1978-12-18 EG EG709/78A patent/EG14095A/xx active
- 1978-12-19 BE BE192414A patent/BE872884A/xx not_active IP Right Cessation
- 1978-12-19 GB GB7848999A patent/GB2010677B/en not_active Expired
- 1978-12-19 DE DE2854723A patent/DE2854723C3/de not_active Expired
- 1978-12-19 NL NLAANVRAGE7812295,A patent/NL179543C/xx not_active IP Right Cessation
- 1978-12-19 CA CA000318174A patent/CA1119095A/en not_active Expired
- 1978-12-20 PL PL1978211979A patent/PL117618B1/pl unknown
- 1978-12-20 FR FR7835817A patent/FR2412314A1/fr active Granted
- 1978-12-20 NO NO784306A patent/NO149316C/no unknown
- 1978-12-21 PH PH21980A patent/PH16435A/en unknown
- 1978-12-21 FI FI783946A patent/FI65166C/fi not_active IP Right Cessation
- 1978-12-21 SE SE7813201A patent/SE431400B/sv not_active IP Right Cessation
- 1978-12-22 DD DD78210129A patent/DD141163A5/de not_active IP Right Cessation
- 1978-12-22 JP JP15909978A patent/JPS54140716A/ja active Granted
- 1978-12-22 IT IT69945/78A patent/IT1109099B/it active
- 1978-12-22 ES ES476703A patent/ES476703A1/es not_active Expired
- 1978-12-22 SU SU782699947A patent/SU997599A3/ru active
- 1978-12-23 KR KR7803902A patent/KR820000045B1/ko not_active Expired
- 1978-12-26 AR AR274956A patent/AR220548A1/es active
- 1978-12-28 AU AU42927/78A patent/AU521538B2/en not_active Expired
1979
- 1979-01-03 MX MX797629U patent/MX5876E/es unknown
- 1979-04-03 US US06/026,496 patent/US4238478A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPS54140716A (en)	1979-11-01
CA1119095A (en)	1982-03-02
NL179543C (nl)	1986-10-01
DK152174C (da)	1988-06-20
FI65166B (fi)	1983-12-30
IL56177A (en)	1981-12-31
GB2010677A (en)	1979-07-04
IL56177A0 (en)	1979-03-12
BE872884A (fr)	1979-06-19
MX5876E (es)	1984-08-16
IN150348B (da)	1982-09-18
JPS6231693B2 (da)	1987-07-09
SU997599A3 (ru)	1983-02-15
ES476703A1 (es)	1979-12-01
NO149316B (no)	1983-12-19
PH16435A (en)	1983-10-07
SE431400B (sv)	1984-02-06
IT1109099B (it)	1985-12-16
DE2854723B2 (de)	1981-02-12
PL211979A1 (da)	1980-02-25
NO149316C (no)	1984-03-28
ATA883578A (de)	1982-02-15
AU4292778A (en)	1979-06-28
NO784306L (no)	1979-06-26
GR65648B (en)	1980-10-15
FR2412314B1 (da)	1982-07-02
KR820000045B1 (ko)	1982-02-06
FI783946A7 (fi)	1979-06-24
GB2010677B (en)	1982-06-16
AU521538B2 (en)	1982-04-08
SE7813201L (sv)	1979-06-24
YU303078A (en)	1983-06-30
DK152174B (da)	1988-02-08
DE2854723C3 (de)	1982-03-25
YU42170B (en)	1988-06-30
DK562178A (da)	1979-06-24
AT368390B (de)	1982-10-11
AR220548A1 (es)	1980-11-14
ZA786978B (en)	1979-11-28
NL7812295A (nl)	1979-06-26
FR2412314A1 (fr)	1979-07-20
DE2854723A1 (de)	1979-06-28
FI65166C (fi)	1984-04-10
PL117618B1 (en)	1981-08-31
US4238478A (en)	1980-12-09
EG14095A (en)	1983-03-31
IT7869945A0 (it)	1978-12-22
CH639280A5 (de)	1983-11-15

Legal Events

Date	Code	Title	Description
1995-08-31	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DE69618018T2 (de)	2002-05-16	Arzneimittel enthaltend botulinum toxin oder neurotoxin und herstellungsverfahren
EP0173241B1 (de)	1991-07-24	Vakzine zur Behandlung der Harnwegsinfektionen
CH651210A5 (de)	1985-09-13	Verfahren zur herstellung einer antikoerper enthaltenden milch zur bekaempfung bakterieller infektionen des magen-darm-traktes.
DE2360118B2 (de)	1980-04-30	Impfstoff gegen Ferkel-Colibacillose
DE2854723C3 (de)	1982-03-25	Hetero-Impfstoff zur therapeutischen Behandlung des Trichomonas -Syndroms und Verfahren zu seiner Herstellung
DE2423129A1 (de)	1974-12-05	Verfahren zur herstellung temperaturempfindlicher, nicht pathogener mutantenstaemme von rinder-adeno-virusstaemmen und diese virusstaemme enthaltende lebendvakzine
KAMINSKI et al.	1976	Human infection with Dermatophilus congolensis
EP0082890B1 (de)	1986-07-30	Verfahren zur Herstellung von immunbiologischen Präparaten, geeignet für den Nachweis von, die Vorbeugung gegen und/oder die Behandlung von Infektionen durch Candida guilliermondii
DE3541044A1 (de)	1987-05-21	Neues, allgemein anwendbares antigen (psc-a) gegen pseudomonas aeruginosa, das als mittel zum schutz gegen pseudomonas aeruginosa-infektion wirkt
DE69306934T2 (de)	1997-05-28	Geflügelkrankheit verursachende neue bakterie und daraus stammender impfstoff
DE69021791T2 (de)	1996-05-02	Verwendung eines phagozytise-aktievierenden Stoffes : LPS oder IL-2 zur Herstellung eines Arzneimittels zur Behandlung von Staphylococcus-aureus-Infektionen bei Kühen.
DE2262427C3 (de)	1980-04-24	Immunostimulierendes Mittel
DE1198489B (de)	1965-08-12	Verfahren zur Herstellung eines Impfstoffes gegen Panleucopenie
DE69535059T2 (de)	2007-01-18	Borrelia burgdorferi bacterin
DE3878982T2 (de)	1993-07-22	Abgeschwaechtes virus und impfstoffe davon zur verwendung gegen infektionen bei gefluegel, verursacht durch truthahn-rhinotracheitis-virus.
DE69121999T2 (de)	1997-04-10	Verfahren und Produkt für die Behandlung von Magenkrankheiten
DE2334376A1 (de)	1974-01-24	Immunologisches produkt, seine verwendung und verfahren zu seiner herstellung
DE2626350C2 (de)	1984-09-13	Impfstoff
DE69208854T2 (de)	1996-10-10	Impfstoff-Zubereitung zur Vorbeugung gegen bei Tieren durch Chlamydia psitacci verursachte Fehlgeburt
DE2700338C2 (de)	1985-11-21	Parenteral injizierbarer Impfstoff für Schweine gegen Infektionen von Bordetella bronchiseptica sowie Verfahren zum Herstellen dieses Impfstoffes
DE859055C (de)	1952-12-11	Verfahren zur Herstellung von Seren und Impfstoffen
AT364452B (de)	1981-10-27	10rfahren zur reinigung und isolierung von e.colienterotoxin
DE2425678A1 (de)	1975-07-24	Verfahren zur herstellung eines impfstoffs gegen infektioese pferdeanaemie
DE1253488B (de)	1967-11-02	Serologisches Reagenz fuer Schwangerschaftsteste in vitro und Methode zu seiner Herstellung
CH612994A5 (en)	1979-08-31	Process for the preparation of coli enterotoxin